Lipocine Inc reports results for the quarter ended in January - Earnings Summary

Lipocine

09/05/2024 14:32

* Lipocine Inc  LPCN.OQ  reported quarterly adjusted
earnings of
66 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -68 cents.  The lone analyst forecast for the quarter was
for a loss of 68 cents per share. 
    * Revenue rose 13,749.4% to $7.62 million from a year ago;
analysts expected zero. 
    * Lipocine Inc's reported EPS for the quarter was 66 cents​.
    * The company reported quarterly net income of $3.51
million.
    * Lipocine Inc shares had fallen by 6.7% this quarter and
gained 73.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 94.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Lipocine Inc is
$33.00 
This summary was machine generated from LSEG data May 9 at 01:31
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.68          0.66           Beat
 Sep. 30 2023      -0.47          -0.42          Beat
 Sep. 30 2023      -0.60          -1.27          Missed
 Jun. 30 2023      -0.64          -0.68          Missed